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Abstract
Background—There is growing evidence in the literature that older patients may not benefit
from more intensive therapy for Head and Neck Squamous Cell Carcinoma (HNSCC). A growing
number of patients with Head and Neck Squamous Cell Carcinoma (HNSCC) are age 65 and
older; however, much of the evidence base informing treatment decisions is based on substantially
younger and healthier clinical trial populations. The purpose of this study was to assess the
patterns of care of older HNSCC patients to better understand how age is associated with
treatment decision.
Methods—Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database
(1992–2007), we identified non-metastatic HNSCC patients (n=10,867) and categorized them into
treatment models: surgery vs. non-surgery, and chemoradiotherapy (CRT) vs. radiotherapy (RT).
Multivariate logistic regression models were used to identify variables associated with the receipt
of surgery and CRT.
Results—Increasing age was associated with decreased odds of receiving CRT (OR = 0.94; 95%
CI 0.93–0.94) but not surgery (OR 1.00; 95% CI 0.99–1.00). Co-morbidity and race were not
associated with receipt of either surgery or CRT. Utilization of CRT increased while surgery
decreased between 1992 and 2007.
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Conclusion—Age may influence the receipt of CRT for older HNSCC patients. There has been
an increasing trend in the receipt of CRT and a decrease in primary surgery.
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Introduction
Within the last decade two large meta-analyses of head and neck squamous cell carcinoma
(HNSCC) patients demonstrated a survival benefit when increasing the intensity of radiation
therapy either by hyperfractionating (smaller doses per fraction) the course of radiation(1) or
by adding concurrent chemotherapy.(2) However, in both studies, intensity of treatment was
not associated with a survival benefit for HNSCC patients older than 71 years of age.(1, 2)
An increasing number of HNSCC patients are 65 or more years of age. Between 1991 and
2009 the NCI Surveillance, Epidemiology and End Results (SEER) registries recorded
168,257 incident malignant head and neck cancer cases, 47% of which occurred in patients
≥ 65 years old.(3, 4) In addition, the incidence of head and neck cancer among older patients
is expected to increase 34% over the next 10 years, and 64% over the next 20 years.(5)
The evidence base informing contemporary management of HNSCC was developed
predominantly on patients younger and healthier than those in the general HNSCC
population.(6–8) Often not included in clinical trials, older patients commonly have multiple
real and perceived complicating factors such as medical comorbidities, decreased functional
reserve, poorer performance status, decreased quality of life, and limited life expectancy.(9,
10) Despite growing numbers of older patients with HNSCC, the dearth of research in this
population has meant that older patients and their doctors often must decide among multiple
treatment modalities with limited evidence-based guidance. Indeed, they face a paradox in
cancer care quality: some have argued that this patient population is undertreated as a result
of unfounded bias and ageism(9), while others have argued that because of their increased
competing mortality they are treated too aggressively.(11)
The goal of this large, population-based study is to establish a baseline understanding of
prevalent treatment patterns experienced by older HNSCC patients. It is important to gain
insight into factors associated with treatment choices for this older population as a
preliminary step prior to characterizing the appropriateness of care. Accordingly, we used
SEER-Medicare linked data to identify clinically distinct treatment cohorts, characterize the
type of treatment modalities they received, and identify how patient and provider
characteristics may be associated with receipt of care and different treatment trends over
time.
Materials and Methods
Data Source
This study used data from the National Cancer Institute’s SEER-Medicare program. Briefly,
the SEER system of population-based cancer registries currently covers approximately 28%
of the US cancer population. Administrative and claims data for those also enrolled in
Medicare allow the examination of comorbid health conditions, treatment utilization, and
select outcomes, as well as many characteristics of the treating providers. These data have
been the basis of innumerous published research studies, and are described extensively
elsewhere.(12)
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Study Population
We identified patients diagnosed with HNSCC between 1992 and 2007. Tumor site was
identified by SEER cancer site codes, and cancer cohorts were grouped as larynx/
hypopharynx (SEER cancer site codes 09, 38), oral cavity (02, 04, 05, and 10), oropharynx
(07 and 08), and other (01, 03, 06, and 37). To maintain cohort treatment eligibility
comparability and sufficient data to characterize baseline comorbidity and first year
treatment utilization, we included patients with non-metastatic HNSCC that was their first
and only cancer among those aged 66 years or older with at least 1 year of Medicare
enrollment. Patients were excluded if they were diagnosed at autopsy or on death certificate,
had metastatic disease at diagnosis, had incomplete claims or less than one year of
continuous claims, or were missing information on date of diagnosis, qualifying treatment
codes, or other covariates. To assure data stability for examination of racial disparities, only
those SEER registries with 5% or greater non-Caucasians were examined(13), including
Greater California, Detroit, Hawaii, New Jersey and Connecticut, Louisiana, and Georgia.
Main Outcomes—Based in the claims data, Current Procedural Terminology (CPT)/
Healthcare Common Procedure Coding System (HCPCS) and International Classification of
Disease (ICD-9) codes for radiation, chemotherapy, and surgery were used to identify
treatments (Table 1). Validated codes were used that were similar to previous SEER-
Medicare studies.(14–16) Based on timing of treatment claims data patients were placed into
7 treatment cohorts (Table 1). These cohorts were used to create two treatment models;
surgery versus non-surgery (cohorts 1–5 vs. 6 & 7) and chemoradiotherapy (CRT) versus
radiotherapy (RT) (cohorts 4 & 7 vs. 2, 3, & 6) (Table 1). These clinically relevant models
were analyzed to answer which variables influence the receipt of definitive surgery and
which affect the addition of chemotherapy to radiation. Of note patients who received post-
radiation neck dissections (codes 40.40, 40.41, 40.42, 38700, 38720, 38724) within 80 days
of first radiation treatment were still considered to be in the CRT alone or RT alone groups.
Covariates—Age was defined by date of diagnosis from SEER files and was analyzed as a
continuous variable. Race (Caucasian or non-Caucasian), gender, marital status, and SEER
region were all determined from SEER files as well. Date of diagnosis was defined as month
and year of diagnosis from the SEER file and Medicare Claims files and was analyzed by 5
year periods (1992–1996, 1997–2001, and 2002–2007). Stage was defined by SEER
Historic Stage A and was assessed across all time periods and was used to control for stage
in our models.(17) There is no available TNM staging for Head and Neck cancer throughout
the time period that we analyzed. This is partly because the TNM system is different among
the different sites of head and neck cancer, and partly because both the TNM staging system
and the available staging information in the SEER database has changed significantly over
time. Therefore we used the historic SEER A staging system. In this staging system distant
stage is defined as patients with metastatic disease (SEER Extent of Disease (EOD) code 85)
or patients with direct extension into ‘remote’ body parts (e.g. Base of tongue cancer with
extension into the mandible). Therefore, even though we excluded patients with metastatic
disease (SEER EOD code 85), there were still patients with ‘distant’ stage in our analysis.
Therefore these ‘distant’ stage patients would have T4a or T4b disease according to current
AJCC staging guidelines and were thus labeled as locally advanced.(18)
Comorbidity was measured based on a weighted Charlson Comorbidity Index (CCI) created
from Medicare claims from one year prior to diagnosis until one month prior to diagnosis of
HNSCC. This method of creating a weighted comorbidity score has previously been
reported and used for both outcomes and patterns of care analyses.(19–21)
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Socioeconomic status (SES) indicators were from SEER census tract data for education and
Medicare files on eligibility for state-buy in for Medicaid. Additional indicator variables
were used to determine the type of treatment facility. These variables included organization
affiliation with NCI Cooperative Groups having head and neck cancer research portfolios
(ACOSOG, ECOG, CALGB, SWOG, NCCTG, and RTOG), NCI cancer center designation,
and medical school affiliation as determined by Medicare Hospital Files.
Statistical Analysis—Bivariate analyses were performed to test the independence of
several of the covariates including census tract education, state buy-in, and organizational
variables. Multivariate logistic regression modeling was performed to identify variables
associated with the two treatment models (surgery vs. non-surgery, and CRT vs. RT). Based
on a priori hypotheses, several interaction terms were tested in the models including: age
with comorbidity, age with race, race with gender, race and SES indicators, and race with
comorbidity. Of note, none of these interaction terms were found to be significant. Model fit
was compared using 2-Log Likelihood. All analyses were performed using SAS v9.2. This
study was approved by the Institutional Review Board at the University of North Carolina at
Chapel Hill (study #10-1985).
Results
Patient and Treatment Characteristics
Median age of all patients was 75 (range 66–106). The majority of patients were Caucasian,
male, married, not eligible for Medicaid, and had no comorbidities based on the CCI (Table
2). Oral cavity was the most common primary site in the surgery vs. non-surgery model
(43%) and hypopharynx + larynx was the most common in the CRT vs. RT model (49%).
Most patients were treated between 2002 and 2007 at cooperative group affiliated hospitals
(Table 2). Fifty eight percent (n=6,347) were treated with definitive surgery and 20%
(n=2,201) were treated with CRT, of which 30% (n=668) were treated postoperatively.
Surgery vs. Non-surgery Model
On multivariate logistic regression comparing patients who received surgery as their primary
treatment to those who received non-surgical treatment (i.e. RT or CRT), we observed that
non-oral cavity primary site, regional or unknown stage, and later era of diagnosis were
significantly associated with decreased receipt of surgical treatment (Table 3). Female
patients were more likely to receive surgery. Of interest, older age (Figure 1a), race,
comorbidity, socioeconomic status, and hospital affiliation were not significantly associated
with receipt of surgery.
Chemoradiotherapy vs. Radiotherapy Model
In this model older age (Figure 1b, Table 4), female gender, and hypopharynx/laryngeal
cancers were significantly associated with decreased receipt of CRT. Non local stage and
oropharyngeal site were significantly associated with receipt of CRT. Comorbidity status,
race, marital status, socioeconomic status, and hospital affiliation correlates were not
significantly associated with treatment.
Patterns of care over time
We observed a decrease in use of surgery and associated increase in non-surgical treatments
(Figure 2a, Table 3) from 1992 to 2007, with the change in treatment trends occurring
around the year 2003. In the year 2006 the number of patients treated with surgery and non-
surgical treatment were similar (Figure 2a). Furthermore there was an increase in the use of
chemotherapy with radiation over the same time period (Figure 2b, Table 4).
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Discussion
The purpose of this study was to establish a baseline understanding of the patterns of care
for older HNSCC patients and to gain insight into factors associated with receipt of CRT vs.
RT and surgery vs. non surgery. Using our cohort of older patients treated in multiple
different settings throughout the US, we found that age may be associated with decreased
receipt of CRT: i.e. the older the patient, the less likely he/she will be treated with CRT (OR
= 0.94; 95% CI 0.93–0.94). However, increasing age was not associated with receipt of
surgery (OR 1.00; 95% CI 0.99–1.00). Similarly race and co-morbidity were not associated
with receipt of treatment in either model. Not surprisingly, regional stage and non-oral
cavity primary tumor site were associated with decreased likelihood of receiving surgery.
We also observed that the rate of non-surgical treatment and CRT use has increased over
time. The increased utilization is consistent with the publication of clinical trials in the
1990’s and early 2000’s supporting the use of “organ preserving” CRT instead of surgery
and the use of concurrent chemotherapy with RT.(22–26) Thus it appears that advancements
in treatment were adopted in older patients. Whether these advancements are appropriate in
older patients is still under debate and was not meant to be addressed in this paper.
Other patterns of care publications (27–29) in older head and neck studies have shown age
to be associated with less intense treatment, and possibly worse outcomes. Most of these
results are based on small single institutional retrospective studies that are biased by
institutional specific treatment policies. Furthermore, previous SEER-Medicare studies may
have misidentified the type of treatments received.(30) Specifically, some studies defined
cancer related surgery and radiation based on SEER codes, which have significantly
changed both in 1998 and 2003 and are known to be not as accurate as Medicare claims. To
our knowledge, we are the first claims based study to distinguish between the treatment
modalities and the order in which the modalities were received. This makes our study both
unique and more clinically relevant. We are also the first study to evaluate how treatment
patterns for this population have changed over time.
One of the limitations of this study involves the analysis of comorbidities. The Charlson
Comorbidity index has been used in multiple retrospective studies and has been shown to be
a good predictor for outcomes in this population.(31) However, one of the commonly
discussed limitations of the Charlson Index in a claims-based setting is that it is often an
indicator of the number of comorbidities and not the severity of the comorbidities. Severity
of comorbidity may be a better predictor for both outcomes and ability to tolerate treatment.
Therefore it is possible that the lack of association between comorbidity and receipt of
treatment is a function of the comorbidity data available in this claims based database.
Similarly, patient functional status is not available in this database and should play an
important role in treatment decision.
We also found stage of disease to be associated with receipt of care. However, stage in this
study is based on the SEER historic A staging system. The SEER historic staging system
relies on very simple parameters such as whether disease is local versus regional versus
distant. The AJCC staging system which is used more often clinically and in prospective
randomized trials was not possible to use in this study due to its unavailability in the SEER-
Medicare database over the time periods and cancer sites assessed. Therefore, the staging
variable, although associated with receipt of care, may not be as reliable at assessing the
severity of the cancer as the AJCC staging system used by most clinicians today.
Additionally, only 8% (n=824) of our cohort was coded with primary site as oropharynx in
the SEER database. Some may suggest this is due in part to misclassification; however,
these results may accurately represent the older population of the SEER-Medicare database.
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The increasing incidence of HPV-related oropharyngeal cancers has been previously shown
to be occurring in cohorts of patients less than 65 years of age.(32) In addition, previous
non-SEER patterns of care studies in older patients with HNSCC also demonstrated lower
rates of oropharyngeal cancer compared to other primary sites in this population.(27, 28)
The use of different primary sites (oral cavity, larynx, and oropharynx) in this study may
also confound some of our results. Primary site plays a major role in the initial treatment
decision (surgery vs. radiation) for HNSCC patients. However, in the majority of previous
epidemiologic studies as well as in previously mentioned meta-analyses these sites were
analyzed together. Therefore we felt it was appropriate to assess the patterns of care of these
sites as one larger cohort.
Building upon this study, our future work will extend this research into the context of
appropriateness of treatment strategies, first by assessing which patients were candidates for
multimodality therapy based on tumor location and stage. A likely consideration will be to
restrict the study population to a single site for which the most detailed data on staging is
available in the SEER-Medicare database – staging data were not adequately granular using
the overall HNSCC population. This will allow an examination of guideline concordance, as
well as the examination of treatment outcomes and toxicity. For these examinations,
propensity-weighted models developed in the current study can be leveraged to adjust for
potential selection bias among the different treatment modalities and combinations. This will
extend our understanding of treatment selection and outcomes among older HNSCC
patients, and may inform the selective inclusion of older patients in Phase III clinical trials
to address questions not easily explored using observational data.
Conclusion
This large claims-based study of HNSCC patients demonstrates that increasing age is
associated with decreased receipt of CRT while the national trend reflects an increase in
receipt of CRT with a coinciding decrease in receipt of surgery over time. This change in
trend may be associated with the publication of evidence supporting CRT in the general
population. Despite evidence of increasing utilization of CRT in older patients, it is unlikely
that an answer to the appropriateness of therapy for this population will be parsed out from a
large retrospective cohort such as SEER-Medicare. There is a significant need for
prospective data in this patient population for a better understanding of how older patients
tolerate and respond to different treatment regimens. Ultimately physicians and their patients
must make individual treatment decisions based on the best available data. However, given
the current lack of data available in this particular patient population, this study provides
rare and much needed insight into treatment decisions among older HNSCC patients.
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Figure 1.
a: Trend in surgery vs. non-surgery with increasing age
b: Trend in chemoradiation vs. radiation with increasing age
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Figure 2.
a: Trend in surgery vs. non-surgery over time.
b: Trend in receipt of chemoradiation vs. radiation over time.
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Table 1
Details of Treatment Cohorts
Treatment
Cohort
Timing ICD-9 Codes CPT/HCPCS/Revenue
Center/Category II/III
codes
Number of
Patients
Surgery Alone
(cohort 1)
60 days prior to or
120 days from date
of diagnosis and
no radiation or
chemotherapy
codes within 120
days of first
qualifying
treatment code
21.5, 21.61,
21.69, 22.31,
22.42, 22.6,
22.60–22.64,
24.31, 25.1–
25.4, 26.2,
26.29, 26.32,
27.3, 27.32,
27.4, 27.42,
27.43, 27.49,
27.55, 27.56,
27.72, 28.92,
29.33, 29.39,
30.0, 30.09,
30.1,30.2,
30.21, 30.22,
30.29, 30.3,
30.4, 31.1, 31.2,
31.29, 31.5,
40.40–40.42,
76.2, 76.31,
76.39, 76.41–
76.45
CPT: 11620–11626,
11640–11646,
21044,21045, 21552–
21558, 30117,30118,
30130–30150, 31200–
31205, 31225–31299,
31300–31420, 38700–
38724, 40810–40819,
41100–41155, 41599,
41825–41827, 42104–
42140, 42410–42450,
42842–42894
2935
Preoperative
Radiation then
Surgery
(cohort 2)
First qualifying
treatment =
radiation within 60
days prior to or
120 days from date
of diagnosis
followed by
surgery within 80
days from start of
radiation
and no
chemotherapy
within 180 days of
surgery
Radiation:
92.21–92.41,
V58.0, V66.1,
V67.1
Surgery: same
as above,
excluding
40.40, 40.41,
40.42 (neck
dissection codes
alone)
Radiation:
CPT: 41019, 77401–
77435, 77499, 77520–
77525, 77750–77799
Category II: 4181F,
3318F, 0520F
Category III: 0073T
HCPCS: G0173,
G0251, G0339,
G0340, S8049
Revenue Center:
0330,0333
Surgery: same as
above, excluding
38700, 38720, and
38724 (neck
dissection alone
codes)
181
Surgery and
Postoperative
Radiation
Alone
(cohort 3)
First qualifying
treatment= surgery
within 60 days
prior to or 120
days from date of
diagnosis,
followed by
radiation within
120 days after
surgery and no
chemotherapy
within 180 days of
surgery
Surgery: same
as cohort 1
Radiation: same
as cohort 2
Surgery: same as
cohort 1
Radiation: same as
cohort 2
2485
Surgery and
Postoperative
Chemoradiation
(cohort 4)
First qualifying
treatment=
surgery within
60 days prior to
or 120 days from
date of
diagnosis,
followed by
radiation and
chemotherapy
Surgery: same
as cohort 1
Radiation: same
as cohort 2
Chemotherapy:
99.25, V58.1,
V58.11,
V58.12, V66.2,
V67.2
Surgery: same as
cohort 1
Radiation: same as
cohort 2
Chemotherapy:
CPT: 96400–96417,
96420–96425, 96440–
96450, 96520–96530,
96542–96549, 99601–
99602
668
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Treatment
Cohort
Timing ICD-9 Codes CPT/HCPCS/Revenue
Center/Category II/III
codes
Number of
Patients
within 120 days of
surgery.
(this cohort
potentially
includes patients
who received
neoadjuvant,
concurrent, and
adjuvant
chemotherapy
related to
radiation)
Category II: 0519F,
3317F
HCPCS: C1166–
C1178, C9004–C9438,
G0355–G0362,
G9021-G9032, J8510-
J999, Q0083-Q0085
Revenue Center:
0331,0332,0335
Surgery
followed by
Chemotherapy alone
(cohort 5)
First qualifying
treatment=
surgery within
60 days prior to
120 days from
date of
diagnosis,
followed by
chemotherapy
within 120 days
and no
radiation within
180 days of
surgery
Surgery: same
as cohort 1
Chemotherapy:
same as cohort
4
Surgery: same as
cohort 1
Chemotherapy:
same as cohort 4
49
Radiation
Alone
(cohort 6)
First qualifying
treatment=
radiation within 60
days prior to or
120 days from date
of diagnosis and
either no surgery
codes, or neck
dissection alone
surgery codes
within 80 days
from first
radiation
and no
chemotherapy
codes within 60
days prior to or
after first radiation
code.
Radiation: same
as cohort 2
Surgery: 40.40,
40.41, 40.42
(neck
dissections
allowed)
Radiation: same as
cohort 2
Surgery: 38700,
38720, and 38724
(neck dissections
allowed)
3016
Chemoradiation
Alone
(cohort 7)
First qualifying
treatment either
radiation or
chemotherapy (as
long as within 90
days between first
chemotherapy and
first radiation) and
first code within
60 days prior to or
120 days following
diagnosis. Either
no surgery codes
or neck dissection
alone codes within
80 days of first
qualifying
treatment code.
(this cohort
potentially
includes patients
who received
neoadjuvant,
concurrent, and
Radiation: same
as cohort 2
Chemotherapy:
same as cohort
4
Surgery: 40.40,
40.41, 40.42
(neck
dissections
allowed)
Radiation: same as
cohort 2
Chemotherapy: same
as cohort 4
Surgery: 38700,
38720, and 38724
(neck dissections
allowed)
1533
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Treatment
Cohort
Timing ICD-9 Codes CPT/HCPCS/Revenue
Center/Category II/III
codes
Number of
Patients
adjuvant
chemotherapy
related to
radiation)
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Table 3
Multivariate analysis of surgery vs. non-surgery.
Patient Characteristics OR 95% CI p-value
SEER region (ref.=
Connecticut and New Jersey)
Detroit 0.98 (0.86 – 1.11) 0.7116
Hawaii 1.06 (0.77 – 1.45) 0.7178
Atlanta and Rural
Georgia
0.94 (0.78 – 1.12) 0.4739
San Francisco, San
Jose, LA and Greater
California
0.86** (0.77 – 0.95) 0.0046
Louisiana 0.70** (0.59 – 0.84) <.0001
Cancer site (ref.= Oral Cavity) Hypopharynx + Larynx 0.27** (0.25 – 0.30) <.0001
Tonsil + Oropharynx 0.19** (0.16 – 0.23) <.0001
Salivary Gland,
Nasopharynx + Middle
Ear
0.62** (0.54 – 0.72) <.0001
Diagnosis era (ref.= 2002–
2007)
1997–2001 1.38** (1.25 – 1.52) <.0001
1992–1996 1.40** (1.26 – 1.56) <.0001
Historic stage A (ref.= In Situ
and localized)
Regional 0.73** (0.67 – 0.80) <.0001
Locally advanced 0.99 (0.83 – 1.18) 0.9184
Unknown/Unstaged 0.54** (0.45 – 0.65) <.0001
Charlson comorbidity index
(ref.= 0)
1+ 0.99 (0.91 – 1.08) 0.8588
Sex (ref.= Male) Female 1.23** (1.12 – 1.35) <.0001
Race (ref.= Caucasian
American)
Non-Caucasian American 0.93 (0.82 – 1.07) 0.3290
Age at diagnosis 1.00 (0.99 – 1.00) 0.3659
Marital status (ref.= Married) Unmarried or
Unknown
1.01 (0.93 – 1.10) 0.8038
Dual eligibility for
Medicare/Medicaid (ref.= No)
Yes 0.96 (0.85 – 1.09) 0.5564
Percent of high school
graduate based on 2000
census data (ref. = Quartile 4:
<25%)
Quartile 1: >=75% 0.99 (0.87 – 1.12) 0.8343
Quartile 2: 50%–<75% 1.01 (0.90 – 1.14) 0.8232
Quartile 3: 25%–<50% 1.01 (0.90 – 1.13) 0.9015
Cooperative group affiliated 0.99 (0.90 – 1.08) 0.8188
NCI cancer center designated 1.25 (0.97 – 1.62) 0.0856
Medical school affiliation 0.95 (0.86 – 1.04) 0.2335
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Table 4
Multivariate analysis of chemoradiation vs. radiation.
Patient Characteristics OR 95% CI p-value
SEER region (ref.=
Connecticut and New Jersey)
Detroit 1.78** (1.49 – 2.12) <.0001
Hawaii 0.38** (0.23 – 0.62) 0.0001
Atlanta and Rural
Georgia
0.78 (0.60 – 1.02) 0.0707
San Francisco, San
Jose, LA and Greater
California
0.83** (0.71 – 0.95) 0.0095
Louisiana 0.71** (0.57 – 0.89) 0.0033
Cancer site (ref.= Oral Cavity) Hypopharynx + Larynx 0.79** (0.69 – 0.90) 0.0006
Tonsil + Oropharynx 1.63** (1.35 – 1.96) <.0001
Salivary Gland,
Nasopharynx + Middle
Ear
1.05 (0.87 – 1.28) 0.5875
Diagnosis era (ref.= 2002–
2007)
1997–2001 0.47** (0.41 – 0.54) <.0001
1992–1996 0.20** (0.17 – 0.23) <.0001
Historic stage A (ref.= In Situ
and localized)
Regional 5.66** (4.90 – 6.54) <.0001
Locally advanced 8.07** (6.51 – 10.00) <.0001
Unknown/Unstaged 3.32** (2.54 – 4.34) <.0001
Charlson comorbidity index
(ref.= 0)
1+ 0.93 (0.83 – 1.04) 0.2035
Sex (ref.= Male) Female 0.79** (0.69 – 0.90) 0.0003
Race (ref.= Caucasian
American)
Non-Caucasian
American
1.09 (0.91 – 1.30) 0.3431
Age at diagnosis 0.94** (0.93 – 0.94) <.0001
Marital status (ref.= Married) Unmarried or Unknown 0.95 (0.84 – 1.08) 0.4296
Dual eligibility for
Medicare/Medicaid (ref.= No)
Yes 1.08 (0.92 – 1.28) 0.3375
Percent of high school
graduate based on 2000
census data (ref. = Quartile 4:
<25%)
Quartile 1: >=75% 1.05 (0.88 – 1.24) 0.5881
Quartile 2: 50%–<75% 1.06 (0.90 – 1.25) 0.4816
Quartile 3: 25%–<50% 0.97 (0.83 – 1.14) 0.7398
Cooperative group affiliated 0.99 (0.87 – 1.12) 0.8273
NCI cancer center designated 1.04 (0.74 – 1.47) 0.8162
Medical school affiliation 0.94 (0.82 – 1.06) 0.3107
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